PharmAla Biotech Logo 800 x 422.png
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
October 08, 2024 08:55 ET | PharmAla Biotech
PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
October 02, 2024 09:20 ET | PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET | PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
PharmAla Biotech Logo 800 x 422.png
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET | PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
PharmAla Biotech Logo 800 x 422.png
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET | PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Biotech Logo 800 x 422.png
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
July 30, 2024 08:55 ET | PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
PharmAla Biotech Logo 800 x 422.png
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
May 03, 2024 11:00 ET | PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
PharmAla Biotech Logo 800 x 422.png
PharmAla Closes Private Placement and Concurrent Debt Settlement
April 19, 2024 08:35 ET | PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
PharmAla Biotech Logo 800 x 422.png
PharmAla Announces Private Placement and Concurrent Debt Settlement
April 10, 2024 16:30 ET | PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
PharmAla Biotech Logo 800 x 422.png
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024 08:58 ET | PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.